Science & Enterprise subscription

Follow us on Twitter

  • A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its se… https://t.co/gNxQafjlOS
    about 5 hours ago
  • New post on Science and Enterprise: Chip-Based RNA Biotech Raises $60M in Venture Funds https://t.co/rHXkiX4vH7 #Science #Business
    about 5 hours ago
  • An easy-to-use device for measuring intraocular pressure responsible for glaucoma is in development by University o… https://t.co/XNVgZXtsw9
    about 9 hours ago
  • New post on Science and Enterprise: Home Eye Pressure Gauge in the Works https://t.co/5OETI9igDD #Science #Business
    about 9 hours ago
  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de… https://t.co/RG11kdD0as
    about 1 day ago

Please share Science & Enterprise

Chip-Based RNA Biotech Raises $60M in Venture Funds

DNA chip graphic

A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its second venture funding round. . . . → Read More: Chip-Based RNA Biotech Raises $60M in Venture Funds

Cancer Screening Analytics Company Acquired in $8B Deal

Blood sample vials

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Mental Health Drug Company Raises $127.5M in IPO

NASDAQ share price display

A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO

Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Human T-cell

A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round. . . . → Read More: Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Antibody Discovery Company Forms, Partners on Covid-19

Network pointer

A new enterprise formed to discover human therapeutic antibodies is partnering with a synthetic biology company to discover Covid-19 antibody treatments. . . . → Read More: Antibody Discovery Company Forms, Partners on Covid-19

Digital Sedation Company Raises $11.8M in Early Funds

Sedakit

A Belgian company creating virtual reality systems for sedation in surgery and invasive procedures is raising €10 million in its first venture funding round. . . . → Read More: Digital Sedation Company Raises $11.8M in Early Funds

Food Allergy Biotech Acquired for $2.6B

Palforzia capsules

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Infographic – Biotech Index Cruising in High Range

Looking back to May shows that NBI has largely settled in to the 4,000 to 4,500 range, without volatile swings in either direction. . . . → Read More: Infographic – Biotech Index Cruising in High Range

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Human B-cell

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal